不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价
x

请在关注微信后,向客服人员索取文件

篇名: 不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价
TITLE:
摘要: 目的:观察不同剂量的阿托伐他汀对慢性硬膜下血肿(CSDH)患者的临床疗效和安全性。方法:选择2013年6月-2015年5月我院CSDH患者128例,按照随机数字表法分为观察组(n=62)和对照组(n=66)。所有患者均给予常规的脑细胞营养治疗;对照组患者给予阿托伐他汀钙片20 mg,po,qd;观察组患者给予阿托伐他汀钙片40 mg,po,qd。两组患者均连续治疗6个月。观察两组患者的临床疗效、神经功能缺损评分标准(CSS)及日常生活能力量表(ADL)评分、血肿量和血清炎症因子[超敏C反应蛋白(hs-CRP)、基质金属蛋白酶9(MMP-9)、白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)]水平,记录治疗过程中的不良反应及治疗后6个月内的复发率。结果:观察组患者脱落2例,对照组患者脱落6例,最终纳入统计的合格病例为120例,两组各60例。观察组患者总有效率(88.3%)明显优于对照组(73.3%),差异有统计学意义(P<0.05)。治疗后1、3、6个月,两组患者CSS评分、血肿量和血清hs-CRP、MMP-9、IL-6、TNF-α水平明显降低,ADL评分明显升高,且观察组患者上述指标改善程度明显优于对照组,差异均有统计学意义(P<0.05)。两组患者各项不良反应的发生率比较,差异均无统计学意义(P>0.05)。对照组患者的复发率(13.3%)明显高于观察组(3.3%),差异有统计学意义(P<0.05)。结论:阿托伐他汀40 mg的日剂量对CSDH患者的临床疗效更好、复发率更低,且安全性良好。
ABSTRACT: OBJECTIVE: To observe the clinical efficacy and safety of different doses of atorvastatin in the treatment of chronic subdural hematoma (CSDH). METHODS: One hundred and tweaty-eight CSDH patients selected from our hospital during Jun. 2013-May 2015 were divided into observation group (n=62) and control group (n=66) in accordance with random number table. Both groups were given conventional treatment of brain cell nutrition. Control group received Atorvastatin tablet 20 mg, po, qd; observation group received Atorvastatin tablet 40 mg, po, qd. Both groups were treated for 6 months. Clinical efficacy, CSS and ADL score, hematoma volume, the levels of serum inflammatory factors (hs-CRP, MMP-9, IL-6, TNF-α) were observed in 2 groups. ADR was recorded during treatment and recurrence rate was also recorded. RESULTS: Two patients withdrew from observation group and 6 from control group. Finally, 120 patients met the criteria were included, with 60 cases in each group. Total response rate of observation group (88.3%) was significantly better than that of control group (73.3%), with statistical significance (P<0.05). After 1, 3, 6 months of treatment, CSS score, hematoma volume, the serum levels of hs-CRP, MMP-9, IL-6 and TNF-α in 2 groups were significantly decreased, while ADL score was increased significantly; the improvement of above indexes in observation group was significantly better than in control group, with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). The recurrence rate of control group (13.3%) was significantly higher than that of observation group (3.3%), with statistical significance (P<0.05).  CONCLUSIONS: Daily dose of shows atorvastatin 40 mg better therapeutic efficacy and lower recurrence rate in the treatment of CSDH with good safety.
期刊: 2017年第28卷第5期
作者: 周宇,陈淳,邓发斌,李元斌,郭川
AUTHORS: ZHOU Yu,CHEN Chun,DENG Fabin,LI Yuanbin,GUO Chuan
关键字: 阿托伐他汀;慢性硬膜下血肿;炎症因子;临床疗效;复发率;安全性
KEYWORDS: Atorvastatin; Chronic subdural hematoma; Inflammatory factor; Clinical efficacy; Recurrence rate; Safety
阅读数: 373 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!